Brain Cancer Clinical Trials
Moffitt Cancer Center’s Neuro-Oncology Program is actively working to improve treatment options, outcomes and quality of life for brain cancer patients now and into the future through our nationally renowned clinical trial program. Before novel treatments are made widely available, they must go through clinical trials that allow researchers to identify when they are most effective, how they interact with other therapies and their success against various types of brain cancer. Advances in understanding the biology of cancer, and efforts to develop new, more effective therapeutics, ultimately result in the development of novel treatments.
What are brain cancer clinical trials?
Clinical trials are controlled medical studies that are used to assess the effectiveness of innovative treatment options. Physicians and scientists are frequently exploring new therapies, such as chemotherapy combinations, biologic therapies and vaccines. Today’s most widely used brain cancer treatments were once evaluated in clinical trials.
#1 Cancer Hospital in Florida
Schedule an AppointmentBrain cancer clinical trials at Moffitt
Moffitt spearheads one of the largest cancer clinical trial programs in the nation. Clinical trials within our brain cancer program include investigations into:
- New ways to use immunotherapy to fight brain cancer
- Gene therapy for brain cancer
- Treatment of leptomeningeal disease (LMD), which currently has few effective treatments
- Use of personalized approaches to match the treatment to the genetics of a patient’s tumor
- Direct delivery of novel therapeutics to tumor tissue
- Imaging techniques
- Immunotherapies
- Radiation therapies
- Vaccine therapies
- Brain metastases diagnostics and treatments
- Neurologic complications of cancers (neuropathies or paraneoplastic syndromes) and its therapies (immunologic therapies, CAR-T therapies, etc.)
Why choose Moffitt?
Research and clinical trials raise the standard of cancer care and continue to bring us closer to a cure. Thanks to Moffitt’s robust clinical trial program and ongoing research efforts, we have been awarded multiple research grants and are recognized as a Comprehensive Cancer Center by the National Cancer Institute. We are currently the only cancer center based in Florida to hold this prestigious designation. Furthermore, our team includes specialists who focus exclusively on brain cancer (primary brain tumors, brain metastases and leptomeningeal disease) and improving treatment options for these diseases, allowing our patients to receive care under the supervision of uniquely experienced professionals.
The decision to participate in a clinical trial is a highly personal one that requires careful consideration. If you would like to receive more information about brain cancer clinical trials at Moffitt and whether or not you are a candidate, contact 1-813-745-6100 or 1-800-679-0775 (toll-free) to speak with a knowledgeable clinical navigator. You may also submit a clinical trials inquiry form online at your convenience.
Medically reviewed by Michael Vogelbaum, MD, PhD, Program Leader, Chief of Neurosurgery, Neuro-Oncology Program.
-
Clinical Trials
CLINICAL TRIAL 20110
GBM Agile: Global Adaptive Trial Master Protocol
Condition: Neurologic Oncology
Intervention: ADI-PEG 20 (); AZD1390 (); BAY 73-4506 (Regorafenib); Lomustine (CeeNU); Paxalisib (); Regorafenib (Stivarga); Temodal (Temozolomide); Temozolomide (); Troriluzole (); VAL-083 (); VT1021 ()
CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)
CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()
CLINICAL TRIAL 21262
A First in Human dose escalation of Dendritic Cell Vaccine (DCV) administered Intrathecally (IT) primed against HER2/HER3 in Patients with Leptomeningeal Disease (LMD) from Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Condition: Neurologic Oncology
Intervention: Dendritic Cell Vaccine ()
CLINICAL TRIAL 22563
A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma
Condition: Neurologic Oncology
Intervention: Lomustine (CeeNU); Paraplatin (carboplatin); Temodal (Temozolomide); Temozolomide (); carboplatin ()
CLINICAL TRIAL 23439
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
Condition: Neurologic Oncology
Intervention: KPT-330 (Selinexor); Selinexor (); Temodal (Temozolomide); Temozolomide ()
CLINICAL TRIAL 23486
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Condition: Neurologic Oncology
Intervention: Radiotherapy (); fSRS ()
CLINICAL TRIAL 23552
Complications and Management of Neurocutaneous Disorders
Condition: Neurologic Oncology
Intervention:
CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
CLINICAL TRIAL 23834
Deciphering the Role of Immune-Related Gene Signature and Tumor-Immune Microenvironment in Glioblastoma
Condition: Neurologic Oncology
Intervention:
Treatment